SCHEMBL23885176

SCHEMBL23885176

N#Cc1c(N)[nH]c2cnccc12

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 2/20 0.55
▸ KDM5C P41229 1/20 0.55
▸ KDM5B Q9UGL1 1/20 0.55
▸ CHUK O15111 6/20 0.50
▸ PDE9A O76083 5/20 0.45
▸ KDM4E B2RXH2 1/20 0.44
▸ GABRP O00591 1/20 0.44
▸ GABRD O14764 1/20 0.44
▸ IKBKB O14920 1/20 0.44
▸ AURKA O14965 1/20 0.44
▸ ALDH1A1 P00352 1/20 0.44
▸ PIM1 P11309 1/20 0.44
▸ TOP1 P11387 1/20 0.44
▸ GABRA1 P14867 1/20 0.44
▸ IDO1 P14902 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ GABRB1 P18505 1/20 0.44
▸ GABRG2 P18507 1/20 0.44
▸ MAOA P21397 1/20 0.44
▸ MAOB P27338 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23885638 0.86 PDE10A (0.50) KDM5AKDM5CKDM5BCHUKPLA2G1B
SCHEMBL22871658 0.78 KDM5A (0.75) KDM5AKDM5CKDM5BCHUKPDE9A
SCHEMBL5858501 0.74 PLA2G1B (0.59) PDE9AKDM4EGABRPGABRDALDH1A1
SCHEMBL13242405 0.73 L3MBTL1 (0.49) KDM5ACHUKKDM4EGABRPGABRD
SCHEMBL20870262 0.71 KDM5A (1.00) KDM5AKDM5CKDM5BCHUKPDE9A
SCHEMBL22298103 0.71 KDM5A (0.69) KDM5AKDM5CKDM5BCHUKPDE9A
SCHEMBL4754631 0.71 KDM5A (0.69) KDM5AKDM5CKDM5BCHUKPDE9A
SCHEMBL13148102 0.70 PDE10A (0.58) KDM5AKDM5CKDM5BCHUKKDM4E
SCHEMBL30322777 0.70 CHUK (0.78) KDM5ACHUKKDM4EGABRPGABRD
SCHEMBL12396541 0.70 CHUK (0.78) KDM5ACHUKKDM4EGABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2023-05-25 — — US disclosed
EP-4125914-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS Biocryst Pharmaceuticals, Inc. (US) 2023-02-08 — — EP disclosed
CN-115427044-A Pyrrolopyrimidines as complement inhibitors 拜奥克里斯特制药公司 2022-12-02 — — CN disclosed
WO-2021202977-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-10-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159536-A1 PYRROLOPYRIMIDINE AMINES AS COMPLEMENT INHIBITORS C5, C9, C1QBP KDM5A 2524/4885KDM5C 2298/4885KDM5B 1958/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback